MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc.
(AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies,
develops and commercializes differentiated products for patients worldwide,
will hold a conference call hosted by Mr. David Allan, Chairman and CEO, at
12:00pm EDT today, August 5, where members of the professional investment
community are invited to discuss the preliminary results obtained from its
open-label, Phase II study (YMB1000-015) of nimotuzumab in patients with
irinotecan-refractory, metastatic colorectal cancer (mCRC) with management.
CONFERENCE CALL DETAILS
DATE: August 5, 2008
TIME: 12:00 PM Eastern Time
DIAL IN NUMBER: 416 644 3419 and 1 800 731 5774
A live audio webcast of the conference call will be available at http://www.ymbiosciences.com.
About YM BioSciences
YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. In addition to nimotuzumab, the Company is developing AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.
This press release may contain forward-looking statements, which
reflect the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include
|SOURCE YM BioSciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved